Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 13;12(20):3596.
doi: 10.3390/nano12203596.

Haptoglobin-Conjugated Gold Nanoclusters as a Nanoantibiotic to Combat Bacteremia

Affiliations

Haptoglobin-Conjugated Gold Nanoclusters as a Nanoantibiotic to Combat Bacteremia

Hsiu-Yi Chu et al. Nanomaterials (Basel). .

Abstract

Gold nanoclusters have revealed great potential as nanoantibiotics due to their superior chemical and physical characteristics. In this study, a peptide with 83 amino acids derived from haptoglobin was utilized as a surface ligand to synthesize gold nanoclusters via a facile hydrothermal approach. Characterization of the structural and optical properties demonstrated the successful synthesis of derived haptoglobin-conjugated gold nanoclusters. The spherical derived haptoglobin-conjugated gold nanoclusters exhibited a (111) plane of cubic gold and an ultra-small size of 3.6 ± 0.1 nm. The optical properties such as ultraviolet-visible absorption spectra, X-ray photoelectron spectroscopy spectra, fluorescence spectra, and Fourier transform infrared spectra also validated the successful conjugation between the derived haptoglobin peptide and the gold nanoclusters surface. The antibacterial activity, reactive oxygen species production, and antibacterial mechanisms of derived haptoglobin-conjugated gold nanoclusters were confirmed by culturing the bacterium Escherichia coli with hemoglobin to simulate bacteremia. The surface ligand of the derived haptoglobin peptide of derived haptoglobin-conjugated gold nanoclusters was able to conjugate with hemoglobin to inhibit the growth of Escherichia coli. The derived haptoglobin-conjugated gold nanoclusters with an ultra-small size also induced reactive oxygen species production, which resulted in the death of Escherichia coli. The superior antibacterial activity of derived haptoglobin-conjugated gold nanoclusters can be attributed to the synergistic effect of the surface ligand of the derived haptoglobin peptide and the ultra-small size. Our work demonstrated derived haptoglobin-conjugated gold nanoclusters as a promising nanoantibiotic for combating bacteremia.

Keywords: antibacterial activity; bacteremia; gold nanoclusters; haptoglobin; hemoglobin; nanoantibiotics; reactive oxygen species.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) TEM image of the derived haptoglobin peptide-conjugated gold nanoclusters (d-Hp-AuNCs), (b) HR-TEM image of d-Hp-AuNCs, (c) Histogram of the size distributions of d-Hp-AuNCs and the Gaussian fitting curve, and (d) EDX analysis of d-Hp-AuNCs.
Figure 2
Figure 2
(a) UV-Vis absorption spectrum of the derived haptoglobin peptide-conjugated gold nanoclusters (d-Hp-AuNCs), (b) XPS spectra of d-Hp-AuNCs (black line), simulated spectrum of Au 4F7/2 (red line), and simulated spectrum of Au 4F5/2 (blue line). (c) Fluorescence spectrum of the derived Hp peptide (black line) and d-Hp-AuNCs (red line).
Figure 3
Figure 3
FTIR spectra of the derived haptoglobin (Hp) peptide and derived Hp-conjugated gold nanoclusters (d-Hp-AuNCs).
Figure 4
Figure 4
Growth curves of Escherichia coli incubated with various solutions, including (i) E. coli, (ii) E. coli + hemoglobin (Hb), (iii) E. coli + Hb + kanamycin, (iv) E. coli + Hb + derived haptoglobin (d-Hp), and (v) E. coli + Hb + d-Hp-gold nanoclusters (AuNCs). The results are presented as the mean ± SD of n = 4 independent experiments. Asterisks indicate significant differences (*** p < 0.001). *** p < 0.001 compared to E. coli.
Figure 5
Figure 5
Photographs of the growth of Escherichia coli in five different bacterial solutions, including (i) E. coli, (ii) E. coli + hemoglobin (Hb), (iii) E. coli + Hb + kanamycin, (iv) E. coli + Hb + derived haptoglobin (d-Hp), and (v) E. coli + Hb + d-Hp-gold nanoclusters (AuNCs).
Figure 6
Figure 6
ROS levels measured with various solutions, including (i) Escherichia coli, (ii) E. coli + hemoglobin (Hb), (iii) E. coli + Hb + derived haptoglobin (d-Hp), and (iv) E. coli + Hb + d-Hp-gold nanoclusters (AuNCs). For the control, the ROS level of E. coli was set to 1.0. The results are presented as the mean ± SD of n = 4 independent experiments. Asterisks indicate significant differences (*** p < 0.001). *** p < 0.001 compared to E. coli.

Similar articles

References

    1. Kadri S.S., Adjemian J., Lai Y.L., Spaulding A.B., Ricotta E., Prevots D.R., Palmore T.N., Rhee C., Klompas M., Dekker J.P., et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 us hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin. Infect. Dis. 2018;67:1803–1814. doi: 10.1093/cid/ciy378. - DOI - PMC - PubMed
    1. Kwong T.N.Y., Wang X.S., Nakatsu G., Chow T.C., Tipoe T., Dai R.Z.W., Tsoi K.K.K., Wong M.C.S., Tse G., Chan M.T.V., et al. Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer. Gastroenterology. 2018;155:383–390. doi: 10.1053/j.gastro.2018.04.028. - DOI - PubMed
    1. De Lorgeril J., Lucasson A., Petton B., Toulza E., Montagnani C., Clerissi C., Vidal-Dupiol J., Chaparro C., Galinier R., Escoubas J.M., et al. Immune-suppression by oshv-1 viral infection causes fatal bacteraemia in pacific oysters. Nat. Commun. 2018;9:4215. doi: 10.1038/s41467-018-06659-3. - DOI - PMC - PubMed
    1. Darton T.C., Zhou L.Q., Blohmke C.J., Jones C., Waddington C.S., Baker S., Pollard A.J. Blood culture-pcr to optimise typhoid fever diagnosis after controlled human infection identifies frequent asymptomatic cases and evidence of primary bacteraemia. J. Infect. 2017;74:358–366. doi: 10.1016/j.jinf.2017.01.006. - DOI - PMC - PubMed
    1. Dagasso G., Conley J., Parfitt E., Pasquill K., Steele L., Laupland K. Risk factors associated with bloodstream infections in end-stage renal disease patients: A population-based study. Infect. Dis. 2018;50:831–836. doi: 10.1080/23744235.2018.1500707. - DOI - PubMed

LinkOut - more resources